UK clinics told to stop prescribing antidiabetes drugs for weight loss, after shortages
BMJ 2023; 382 doi: https://doi.org/10.1136/bmj.p1693 (Published 21 July 2023) Cite this as: BMJ 2023;382:p1693
- Gareth Iacobucci
- The BMJ
The UK government has urged healthcare providers to stop prescribing appetite suppressant drugs for weight loss because current shortages were creating “serious clinical implications” for patients with type 2 diabetes.
In a national patient safety alert issued on 18 July,1 the Department of Health and Social Care for England and the Medicines and Healthcare Products Regulatory Agency said there were “very limited, intermittent supplies” of all glucagon-like peptide-1 (GLP-1) receptor agonists because of the rise in demand for the drugs to …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.